Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomised, Double-blind, Parallel-group, 42-week Dose-finding Trial for BI 3034701 Administered Subcutaneously Compared to Placebo in Participants With Obesity or Overweight

NCT07662122 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT07662122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07662122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomised, Double-blind, Parallel-group, 42-week Dose-finding Trial for BI 3034701 Administered Subcutaneously Compared to Placebo in Participants With Obesity or Overweight
Lead sponsor
Boehringer Ingelheim
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 30, 2026
Completion date
July 10, 2027
Enrollment
344 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, overweight